SEB Asset Management’s Praxis Precision Medicines PRAX Stock Holding History

SEB Asset Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.3M	Buy	+42,705	New	+$13.5M	0.05%	283

Other funds holding PRAX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SEB Asset Management's PRAX Position: Q2 2026 in Review

SEB Asset Management opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 42,705 shares worth $14.3M. The stake represents 0.05% of the portfolio and ranks #283 among its holdings.

61 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

SEB Asset Management held 42,705 shares of Praxis Precision Medicines worth $14.3M as of Q2 2026.
Praxis Precision Medicines was a new SEB Asset Management position in Q2 2026.
Praxis Precision Medicines made up 0.05% of SEB Asset Management's portfolio in Q2 2026, its #283 holding.
61 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.